



Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences

PALO ALTO, Calif., November 10, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at two investor conference events in November:

- Stifel 2021 Virtual Healthcare Conference
 - Wednesday, November 17 at 4:40 PM ET (live)
- Jefferies London Healthcare Conference
 - Thursday, November 18 (pre-recorded)

Eiger will also host one-on-one meetings with investors at both conferences.

Webcasts of the presentations will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section. The Stifel presentation will be webcast live, and a replay will be available approximately one hour following the live event. The Jefferies presentation will be available at 3:00 AM ET on Thursday, November 18, 2021.

About Eiger

Eiger is a commercial stage biopharmaceutical company focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy Designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

SOURCE Eiger BioPharmaceuticals, Inc.

Investors and Media:

Sri Ryali

Chief Financial Officer

Email: sryali@eigerbio.com

Phone: 1-650-272-6138 ext. 1007